PALATINE, IL--(Marketwired - Apr 22, 2013) - Acura Pharmaceuticals, Inc. (
To participate in the live conference call, please dial 888-427-9419 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 1259095.
A replay of the call will be available beginning May 6, 2013 at 11:30 a.m. ET and ending on May, 27, 2013 on the company's website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 1259095.
About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE™ technologies. In June 2011, the U.S. Food and Drug Administration approved OXECTA® which incorporates the AVERSION® technology. The Company has a development pipeline of additional AVERSION® technology products including other opioids and its IMPEDE™ technology for pseudoephedrine hydrochloride products.
The trademark OXECTA® is owned by Pfizer Inc.